Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/2050640618764940 http://scihub22266oqcxt.onion/10.1177/2050640618764940 C6047294!6047294!30023070     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       United+European+Gastroenterol+J 2018 ; 6 (6): 919-25 Nephropedia Template TP {{tp|p=30023070|t=2018. Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts |pdf=|usr=}}{{30023070}} gab.com Text Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts JO: United European Gastroenterol J http://www.kidney.de/pget.php?&tw=1&pmid=30023070 #FOAvip Background: Over the past decades, multiple approaches to aspiration sclerotherapy of large symptomatic hepatic cysts have been investigated. However, comparative data are scarce. Objective: The objective of this article is to compare cyst reduction, symptomatic relief, and adverse events between ethanol sclerotherapy and polidocanol sclerotherapy. Methods: This retrospective study included adults having a symptomatic hepatic cyst treated at a European tertiary referral center with ethanol sclerotherapy (Center 1) or polidocanol-sclerotherapy (Center 2). We compared cyst diameter reduction (%) and symptom improvement (yes/no) within 12 months? post-treatment between centers using multivariate regression analyses adjusted for confounding factors. Finally, we compared adverse events using Fisher?s exact test. Results: We included 71 patients from Center 1 and 66 patients from Center 2 (median age 57 years; 126/137 (92%) female). Cyst reduction was comparable between Centers 1 and 2: 37.5% (IQR 15.7?61.0%) versus 44.2% (IQR 24.6?60.5%), respectively (p?=?0.35). Correspondingly, symptomatic relief was comparable: 30/53 (56.6%) versus 43/66 (65.2%), respectively (p?=?0.88). Center 1 reported significantly more (11 versus 3; p?=?0.047) adverse events than Center 2. Conclusion: We found comparable cyst reduction and symptomatic relief rates between ethanol- and polidocanol sclerotherapy, while adverse events occurred more often in the ethanol group. Prospective studies focused on clinical response are needed to further explore differences between approaches. Twit Text FOAVip Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts ????United European Gastroenterol J http://www.kidney.de/pget.php?&tw=1&pmid=30023070 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30023070 #FOAvip English Wikipedia <ref>{{Cite pmid|30023070}}</ref> Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts #MMPMID30023070 Wijnands TF; Schoenemeier B; Potthoff A; Gevers TJ; Groenewoud H; Gebel MJ; Rifai K; Manns MP; Drenth JP United European Gastroenterol J 2018[Jul]; 6 (6): 919-25 PMID30023070show ga Background: Over the past decades, multiple approaches to aspiration sclerotherapy of large symptomatic hepatic cysts have been investigated. However, comparative data are scarce. Objective: The objective of this article is to compare cyst reduction, symptomatic relief, and adverse events between ethanol sclerotherapy and polidocanol sclerotherapy. Methods: This retrospective study included adults having a symptomatic hepatic cyst treated at a European tertiary referral center with ethanol sclerotherapy (Center 1) or polidocanol-sclerotherapy (Center 2). We compared cyst diameter reduction (%) and symptom improvement (yes/no) within 12 months? post-treatment between centers using multivariate regression analyses adjusted for confounding factors. Finally, we compared adverse events using Fisher?s exact test. Results: We included 71 patients from Center 1 and 66 patients from Center 2 (median age 57 years; 126/137 (92%) female). Cyst reduction was comparable between Centers 1 and 2: 37.5% (IQR 15.7?61.0%) versus 44.2% (IQR 24.6?60.5%), respectively (p?=?0.35). Correspondingly, symptomatic relief was comparable: 30/53 (56.6%) versus 43/66 (65.2%), respectively (p?=?0.88). Center 1 reported significantly more (11 versus 3; p?=?0.047) adverse events than Center 2. Conclusion: We found comparable cyst reduction and symptomatic relief rates between ethanol- and polidocanol sclerotherapy, while adverse events occurred more often in the ethanol group. Prospective studies focused on clinical response are needed to further explore differences between approaches. äEthanol sclerotherapy or polidocanol sclerotherapy for symptomatic hep(epmc).pdf DeepDyve Pubget Overpricing